FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator?s Choice of Chemotherapy in Women with Folate Receptor ??positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Save

Date Added
November 8th, 2016
PRO Number
Pro00054790
Researcher
Whitney Graybill
Keywords
Cancer, Cancer/Gynecological, Drug Studies, Women's Health
Summary

This is a Phase 3, open label, randomized study to compare the progression free survival (PFS) of patients randomized to IMGN853 versus selected standard of care chemotherapy.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Save

Date Added
February 9th, 2016
PRO Number
Pro00050262
Researcher
Whitney Graybill
Keywords
Cancer, Cancer/Gynecological, Drug Studies, Obstetrics and Gynecology, Women's Health
Summary

This study is for female subjects with previously untreated Stage III or IV high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. The investigational drug in this study is Veliparib (ABT-888). The purpose of this study is to compare the combination of carboplatin, paclitaxel and veliparib to carboplatin, paclitaxel, and placebo followed by continued therapy with either veliparib or placebo to determine if it slows the progression of your cancer.

Institution
MUSC
Recruitment Contact
HCC Clincial Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction Save

Date Added
June 16th, 2015
PRO Number
Pro00044409
Researcher
Whitney Graybill
Keywords
Bowel, Cancer
Summary

This study is for patients who have a malignant bowel obstruction and their doctor is not sure if surgery or non-surgical treatment will be better for the condition.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Pilot Study Evaluating Racial Disparity, Environmental Toxin Exposure and Regulation of Anti-Inflammatory Mediators as Risk Factors for Endometrial Carcinogenesis Save

Date Added
May 22nd, 2014
PRO Number
Pro00030149
Researcher
Whitney Graybill
Keywords
Cancer, Environmental Factors
Summary

The purpose of this study is to determine if environmental toxin exposure differs in African American women as compared to White women with endometrial cancer and to evaluate the relationship between demographic variables and toxin level.

Institution
MUSC
Recruitment Contact
Tamara Jenkins
843-792-6992
saundert@musc.edu

A pilot study evaluating vitamin D deficiency and risk of aggressive uterine cancer in African American as compared to White women Save

Date Added
May 19th, 2014
PRO Number
Pro00030938
Researcher
Whitney Graybill
Keywords
Cancer/Gynecological, Women's Health
Summary

The purpose of this study is to evaluate vitamin D levels in African American and White women who present with a new diagnosis of uterine cancer.

Institution
MUSC
Recruitment Contact
Tamara Jenkins
843-792-6992
saundert@musc.edu

A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Save

Date Added
April 30th, 2014
PRO Number
Pro00034096
Researcher
Whitney Graybill
Keywords
Cancer/Gynecological, Women's Health
Summary

This study is for adult women who have advanced or recurrent endometrial (uterine) cancer. The purpose is to find out if the drug combination of paclitaxel, carboplatin and metformin works better than paclitaxel and carboplatin alone in treating uterine cancer.

Institution
MUSC
Recruitment Contact
Sarah Booker
843-792-9190
bookers@musc.edu

Change_preferences

-- OR --

Create_login